AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- 4DMedical revenue surges 103% year-to-date
- Strategic U.S. and Australian partnerships strengthen growth
- Regulatory milestones advance global market expansion
4DMedical (ASX:4DX) has reported an impressive 103% increase in operating revenue year-to-date for FY2025, reaching $4.5 million. In the third quarter alone, the company generated $1.6 million in revenue, reflecting an 8% increase over the previous quarter. Gross margins remained exceptionally high at 91.4%, highlighting the company's operational efficiency. SaaS revenue growth continued strongly, with underlying quarterly figures adjusted up by 42%. As of 31 March 2025, 4DMedical maintained a healthy cash balance of $16.8 million, providing solid financial footing for ongoing initiatives. Among ASX healthcare stocks, 4DMedical stands out due to its strong financial performance and robust growth trajectory.
Strategic Growth Through Key Partnerships
The company's sales pipeline received a significant boost with the addition of new reference sites across the United States and Australia. A major milestone was the renewal of a three-year SaaS agreement with the Cleveland Clinic, valued at a minimum of A$227,000. Moreover, pilot programs with Integral Diagnostics (ASX:IDX) and Qscan have been successfully transitioned into full commercial agreements. In the Australian market, partnerships with Qscan Radiology Clinics and Lake Imaging are expected to broaden access to 4DMedical’s SaaS platform, supporting increased adoption of its advanced respiratory imaging technologies.
Focused Cost Management Enhancing Operational Efficiency
4DMedical also implemented a focused cost reduction initiative, resulting in annualised savings of $6.5 million. This was achieved by optimizing the global workforce, reducing headcount from 142 to 117 full-time equivalents. Operating expenses in Q3 FY2025 were $1.4 million lower than in the previous quarter, attributed to tighter controls on corporate expenditures and research and development costs. These measures contribute significantly to strengthening the company’s financial resilience while maintaining a focus on innovation.
Regulatory Progress Paving the Way for Market Expansion
Progress on regulatory fronts continues, with 4DMedical nearing the submission of CT:VQ™ for FDA 510(k) clearance in the United States. The CT:VQ™ platform has captured strong interest among academic medical centers and key healthcare providers, such as Brooke Army Medical Center. Additionally, the CT LVAS™ platform received regulatory approval in Canada, adding another market where 4DMedical’s technology can make an impact.
Founder and CEO Andreas Fouras emphasized the momentum, noting that March marked the company's highest-ever monthly sales. The upcoming FDA submission for CT:VQ™ is poised to revolutionize the billion-dollar respiratory diagnostics segment by offering a faster, safer, and more accessible alternative to traditional Nuclear VQ imaging.
As the company moves through the rest of 2025, its combination of financial growth, strategic partnerships, and regulatory advances position it strongly for continued expansion in the global healthcare market.
